| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| oxymetazoline | alpha-1a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.39 | approved,investigational | partial agonist,agonist |
| oxymetazoline | alpha-1a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.39 | approved,investigational | partial agonist |
| oxymetazoline | alpha-1b adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.27 | approved,investigational | agonist |
| oxymetazoline | alpha-1d adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.45 | approved,investigational | agonist |
| oxymetazoline | alpha-2a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.56 | approved,investigational | agonist,partial agonist |
| oxymetazoline | alpha-2b adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.23 | approved,investigational | agonist |
| oxymetazoline | alpha-2c adrenergic receptor | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.13 | approved,investigational | agonist |
| oxymetazoline | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
NA | approved,investigational | agonist |
| oxymetazoline | 5-hydroxytryptamine receptor 1b | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.08 | approved,investigational | agonist |
| oxymetazoline | 5-hydroxytryptamine receptor 1d | small molecule | NA | drugbank , DGIDB | Rosacea[MeSHID:D012393] Operative Surgical Procedures[MeSHID:D013514] Erythema[MeSHID:D004890] Eye[MeSHID:D005123] Ear structure[MeSHID:D004423] Blepharoptosis[MeSHID:D001763] Pharyngeal structure[MeSHID:D010614] Off-Label Use[MeSHID:D056687] Postoperative Hemorrhage[MeSHID:D019106] Nose[MeSHID:D009666] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Endophthalmitis[MeSHID:D009877] |
0.09 | approved,investigational | agonist |
| click here to return to the previous page | ||||||||